IL94052A - Pharmaceutical preparations containing cytokines for the treatment of pre-neoplastic lesions and the use of the above cytokines - Google Patents

Pharmaceutical preparations containing cytokines for the treatment of pre-neoplastic lesions and the use of the above cytokines

Info

Publication number
IL94052A
IL94052A IL9405290A IL9405290A IL94052A IL 94052 A IL94052 A IL 94052A IL 9405290 A IL9405290 A IL 9405290A IL 9405290 A IL9405290 A IL 9405290A IL 94052 A IL94052 A IL 94052A
Authority
IL
Israel
Prior art keywords
cytokines
cytokine
combination
treatment
preneoplastic lesions
Prior art date
Application number
IL9405290A
Other languages
English (en)
Hebrew (he)
Other versions
IL94052A0 (en
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IL94052A0 publication Critical patent/IL94052A0/xx
Publication of IL94052A publication Critical patent/IL94052A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
IL9405290A 1989-04-11 1990-04-09 Pharmaceutical preparations containing cytokines for the treatment of pre-neoplastic lesions and the use of the above cytokines IL94052A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3911720 1989-04-11
DE4005416 1990-02-21

Publications (2)

Publication Number Publication Date
IL94052A0 IL94052A0 (en) 1991-01-31
IL94052A true IL94052A (en) 1995-06-29

Family

ID=25879777

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9405290A IL94052A (en) 1989-04-11 1990-04-09 Pharmaceutical preparations containing cytokines for the treatment of pre-neoplastic lesions and the use of the above cytokines

Country Status (14)

Country Link
US (1) US5128126A (enExample)
EP (1) EP0392300B1 (enExample)
JP (1) JPH02304027A (enExample)
KR (1) KR900015754A (enExample)
AT (1) ATE79763T1 (enExample)
AU (1) AU638982B2 (enExample)
CA (1) CA2014130A1 (enExample)
DE (1) DE59000270D1 (enExample)
DK (1) DK0392300T3 (enExample)
ES (1) ES2034790T3 (enExample)
GR (1) GR3005528T3 (enExample)
HU (1) HU206834B (enExample)
IE (1) IE64765B1 (enExample)
IL (1) IL94052A (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605712B1 (en) * 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
JP2597953B2 (ja) * 1991-12-10 1997-04-09 大塚製薬株式会社 制癌剤
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5571797A (en) * 1994-05-11 1996-11-05 Arch Development Corporation Method of inducing gene expression by ionizing radiation
WO1999040929A1 (en) * 1998-02-12 1999-08-19 The General Hospital Corporation Methods to potentiate cancer therapies
US6719977B1 (en) * 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies
ES2529300T3 (es) 2000-04-12 2015-02-18 Novozymes Biopharma Dk A/S Proteínas de fusión de albúmina
US7431920B2 (en) * 2000-07-19 2008-10-07 Pepgen Corporation Method of treating IL-10 deficiency
US20040247565A1 (en) * 2000-07-19 2004-12-09 Chih-Ping Liu Method of treatment using interferon-tau
US20050118138A1 (en) * 2000-07-19 2005-06-02 Chih-Ping Liu Method of treatment using interferon-tau
US20050118137A1 (en) * 2000-07-19 2005-06-02 Chih-Ping Liu Method of treatment using interferon-tau
US20050201981A1 (en) * 2004-03-10 2005-09-15 Chih-Ping Liu Method of optimizing treatment with interferon-tau
US20050226845A1 (en) * 2004-03-10 2005-10-13 Chih-Ping Liu Method of treatment using interferon-tau
US20050084478A1 (en) * 2000-10-17 2005-04-21 Chih-Ping Liu Combination therapy using interferon-tau
US20020150552A1 (en) * 2000-09-12 2002-10-17 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20030082685A1 (en) * 2001-04-06 2003-05-01 WEICHSELBAUM Ralph R. Chemotherapeutic induction of egr-1 promoter activity
US20040242523A1 (en) * 2003-03-06 2004-12-02 Ana-Farber Cancer Institue And The Univiersity Of Chicago Chemo-inducible cancer gene therapy
US8034791B2 (en) 2001-04-06 2011-10-11 The University Of Chicago Activation of Egr-1 promoter by DNA damaging chemotherapeutics
WO2002097038A2 (en) * 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
WO2003060071A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
CA2536041A1 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
US20060078942A1 (en) * 2004-03-10 2006-04-13 Pepgen Corporation Method of treatment using interferon-tau
US20080025948A1 (en) * 2004-03-10 2008-01-31 Chih-Ping Liu Methods of Treatment Using Interferon-Tau
EP1781284B1 (en) * 2004-08-25 2010-10-13 The University of Chicago Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma
US20080241100A1 (en) * 2007-03-27 2008-10-02 Stefan Strobl Pharmaceutical composition comprising a cytokine
EP1977759A1 (en) * 2007-03-27 2008-10-08 4Sc Ag Pharmaceutical composition comprising a cytokine
JP2010522724A (ja) * 2007-03-27 2010-07-08 ４エスツェー アクチェンゲゼルシャフト サイトカインを含有する医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983001198A1 (en) * 1981-10-08 1983-04-14 Kurt Frimann Berg Method and composition for treating a patient suffering from interferon-susceptible disorder
AU9051882A (en) * 1981-10-08 1983-04-27 Berg, Kurt Frimann Method and composition for treating a patient suffering from interferon-susceptible disorders
EP0077063B1 (en) * 1981-10-13 1988-03-16 Exovir, Inc. Interferon-containing compositions and the use of these compositions in the treatment of herpetic infections, pre-malignant skin lesions, skin malignancies and psoriasis
US4507281A (en) * 1981-10-13 1985-03-26 Exovir, Inc. Interferon-containing compositions
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4605555A (en) * 1984-09-20 1986-08-12 Sun Star Kabushiki Kaisha Composition and method for treating keratosic disorder of skin and mucosa
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like

Also Published As

Publication number Publication date
IL94052A0 (en) 1991-01-31
CA2014130A1 (en) 1990-10-11
EP0392300A1 (de) 1990-10-17
HU902145D0 (en) 1990-07-28
EP0392300B1 (de) 1992-08-26
HUT54303A (en) 1991-02-28
ATE79763T1 (de) 1992-09-15
AU638982B2 (en) 1993-07-15
AU5310590A (en) 1990-10-18
IE901297L (en) 1990-10-11
KR900015754A (ko) 1990-11-10
US5128126A (en) 1992-07-07
DK0392300T3 (da) 1992-09-28
GR3005528T3 (enExample) 1993-06-07
HU206834B (en) 1993-01-28
ES2034790T3 (es) 1993-04-01
DE59000270D1 (de) 1992-10-01
JPH02304027A (ja) 1990-12-17
IE64765B1 (en) 1995-09-06

Similar Documents

Publication Publication Date Title
US5128126A (en) Use of pharmaceutical compositions containing at least one cytokine for the systemic treatment of preneoplastic lesions
US4791101A (en) Synergistic mixtures of interferons and tumor necrosis factor
RU2128056C1 (ru) Способы и препараты для лечения заболеваний интерфероном, характеризующиеся сниженными побочными эффектами
EP0741577B1 (en) The use of interferon subtype alpha 8 in the preparation of medicaments to treat viral infections of the liver
EP0299745B1 (en) Double-stranded RNA correction of RNase L deficiency
EP0488718B1 (en) Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
KR0165674B1 (ko) 원발성 흉막암의 치료를 위한 제약 조성물
Awisati et al. The role of interferon-α in the management of myelomatosis
WO2004022088A1 (en) Interferon and immunoglobulin fc fragment hybrid
JP2008031179A (ja) β−インターフェロンを使用して再狭窄を治療する方法
KR0168421B1 (ko) 인간 인터루킨 2 활성을 갖는 폴리펩티드 기재의 항종양제 조성물
Beaupain et al. Effects of human recombinant interferons-α2,-β and-γ on growth and survival of human cancer nodules maintained in continuous organotypic culture
CA1291706C (en) COMBINATION THERAPY USING INTERFERON-.beta. AND INTERLEUKIN-2
EP0687470A2 (en) Agents for treating metabolic bone diseases
Carter et al. Independent evolution of antiviral and growth-modulating activities of interferon
Chapekar et al. Potentiation of the cytocidal effect of human immune interferon by different synthetic double-stranded RNAs in the refractory human colon carcinoma cell line BE
Fiers et al. Tumor necrosis factor: a potential antitumor agent?
EP1471974B1 (en) Tumor necrosis factor combined with interferon in demyelinating diseases
EP0670165B1 (en) Use of seminal ribonuclease as antimetastatic compound
KR0169975B1 (ko) 감마 인터페론 활성을 갖는 폴리펩티드를 함유하는 원발성 흉막암 치료용 제약 조성물
Richtsmeier The interferons
KOREN et al. Modulation of peripheral leukocyte counts and bone marrow function in mice by oral administration of interleukin-2
EP1285663B1 (en) Protective interferon-beta against reinfection after liver transplantation
Miyake et al. Synergistic effect of natural human tumor necrosis factors α and β in the clonogenic assay
JPS62265233A (ja) インタ−フエロン−β及びインタ−ロイキン−２を含有する医薬組成物

Legal Events

Date Code Title Description
KB Patent renewed
RH Patent void